Navigation Links
Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
Date:3/24/2008

IV programs;

-- Presented preclinical data demonstrating potent activity and favorable

resistance profiles for our non-nucleoside reverse transcriptase

inhibitor (NNRTI) family of compounds against HIV at the 15th Annual

Conference on Retroviruses and Opportunistic Infections (CROI);

-- Presented favorable anti-tumor preclinical data on RDEA119 at the 2007

AACR-NCI-EORTC International Conference on Molecular Targets and

Cancer Therapeutics; and

-- Relocated our corporate headquarters and research laboratories to San

Diego's biotechnology corridor.

2008 Anticipated Key Program Milestones

In 2008, Ardea anticipates accomplishing the following milestones:

HIV

-- Initiate a Phase 2b trial of RDEA806 in patients with HIV in the

second quarter of 2008;

-- Complete a first-in-human micro-dosing study of our second generation

NNRTI, RDEA427, in the first quarter of 2008;

-- Initiate a Phase 1 trial of RDEA427 in the second half of 2008; and

-- Present the full results of our Phase 2a proof-of-concept study of

RDEA806 at a scientific conference in the second half of 2008.

Gout/Inflammation

-- Initiate a Phase 2 dose-finding trial for the treatment of gout in

the second quarter of 2008 with results expected in the second half

of 2008; and

-- Initiate a Phase 2a trial with RDEA119 for the treatment of

inflammatory disease in the second quarter of 2008.

Cancer

-- Complete and report data from the Phase 1 trial of RDEA119 in

patients with advanced cancer in the second half of 2008;

-- Initiate Phase 2 trials of RDEA119 in combination with other anti

cancer agents in the second half of 2008; and

-- Initiate a Phase 1 trial of our second generation MEK inhibitor in

the second half of 2008.

<
'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
3. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
4. Numira Biosciences Names New Board Member
5. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
6. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
9. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2
... Louisville Health Sciences Center faculty and students made an ... four regions of Kentucky served by UofL Area Health ... donated services valued at $5,606,599 while their students spent ... in the four regions. These regions encompass 56 counties ...
... HealthDay Reporter , WEDNESDAY, Jan. 11 (HealthDay News) -- Americans ... life expectancy going from 78.6 years in 2009 to 78.7 ... a percent between 2009 and 2010, and hit the lowest ... the latest set of data from the U.S. Centers for ...
... , WEDNESDAY, Jan. 11 (HealthDay News) -- The first major gene ... been identified by scientists. Men who inherit the mutation in ... of developing prostate cancer, according to the study in the Jan. ... The HOXB13 gene plays an important role in the development ...
... WEDNESDAY, Jan. 11 (HealthDay News) -- A new type of ... to help re-educate rogue immune system cells, which allows cells ... The treatment, which combines a patient,s immune system cells with ... people with long-standing diabetes who were believed to have no ...
... News) -- A small study that offers new insight into ... effective treatments for people with drinking problems. Researchers used ... alcohol in the brains of 13 heavy drinkers and a ... In all of the participants, drinking alcohol triggered the ...
... have discovered that a subtype of leukemia characterized by ... distinctly different from a seemingly similar leukemia associated with ... Jude Children,s Research Hospital Washington University Pediatric Cancer ... treating patients with this more aggressive cancer. ...
Cached Medicine News:Health News:UofL centers have economic impact in excess of $5.7 million 2Health News:UofL centers have economic impact in excess of $5.7 million 3Health News:Americans Living Longer, Report Finds 2Health News:Americans Living Longer, Report Finds 3Health News:Scientists Identify Inherited Prostate Cancer Gene 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 3Health News:Alcohol Targets Brain 'Reward Centers' in Heavy Drinkers 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 3Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 4
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 2015 Perrigo Company plc ("Perrigo") (NYSE: ... ("Mylan") (NASDAQ: MYL ) shareholder vote regarding its ... views of Mylan,s offer to Perrigo shareholders have always ... Board,s careful reflection of the value available to Perrigo ... that Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: